By Fineline Cube 
Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459) for Rentosertib (ISM001-055), a potential first-in-class small-molecule inhibitor for idiopathic pulmonary fibrosis (IPF) discovered using the company’s proprietary generative AI platform, Pharma.AI. The molecule has received Orphan Drug Designation from the U.S. FDA and Breakthrough Therapy Designation from China’s CDE.
Clinical Trial Design & Regulatory Status
| Item | Detail |
|---|---|
| Company | Insilico Medicine (HKG: 3696) |
| Drug Candidate | Rentosertib (ISM001-055) |
| Indication | Idiopathic pulmonary fibrosis (IPF) |
| Trial Phase | Phase 3 |
| Trial Identifiers | CTR20262475 (China), NCT07687459 (US) |
| Design | Randomized, double-blind, placebo-controlled |
| Duration | 52 weeks |
| Enrollment | ~320 subjects across 47 research centers (China) |
| Dosing | Once-daily oral administration |
| Regulatory Designations | FDA Orphan Drug Designation CDE Breakthrough Therapy Designation |
Primary & Secondary Endpoints
- Primary Endpoint: Annual rate of decline in forced vital capacity (FVC) over 52 weeks
- Secondary Endpoints:
- Time to first disease progression
- Changes in diffusing capacity of the lungs for carbon monoxide (DLCO)
- Quality-of-life measures based on validated questionnaire assessments
The trial’s robust endpoint selection aligns with regulatory requirements for IPF drug approval and addresses both physiological and patient-reported outcomes critical to demonstrating clinical benefit.
AI-Driven Discovery & Development Innovation
Pharma.AI Platform: Rentosertib represents one of the first clinical-stage molecules entirely discovered and optimized using Insilico’s generative AI platform, which integrates target identification, molecular generation, and preclinical validation in an end-to-end computational workflow.
Development Timeline Acceleration: The AI-driven approach enabled Insilico to progress from target identification to IND submission in approximately 18 months, significantly faster than traditional drug discovery timelines of 4-6 years.
First-in-Class Potential: As a novel mechanism targeting pathways distinct from current IPF therapies (pirfenidone and nintedanib), Rentosertib offers potential for improved efficacy, tolerability, or combination therapy opportunities.
Market Opportunity & Competitive Landscape
- Unmet Medical Need: IPF affects approximately 1 million patients globally with a median survival of 3-5 years post-diagnosis, creating significant demand for more effective therapies.
- Market Size: The global IPF therapeutics market is projected to reach $4.5 billion by 2030, with limited treatment options driving premium pricing for innovative mechanisms.
- Regulatory Advantages: Dual designation as Orphan Drug (FDA) and Breakthrough Therapy (CDE) provides expedited review pathways, extended market exclusivity, and enhanced commercial positioning.
Strategic Implications for AI Drug Discovery
- Validation Milestone: Successful Phase 3 initiation represents a critical validation point for AI-native drug discovery companies, demonstrating the ability to generate clinically viable candidates with novel mechanisms.
- Platform De-risking: Positive Phase 3 data would significantly de-risk Insilico’s entire Pharma.AI platform, potentially accelerating partnerships and pipeline advancement across multiple therapeutic areas.
- Investor Confidence: The milestone reinforces the investment case for AI-driven biotechnology, with implications for the broader computational drug discovery ecosystem.
Forward‑Looking Statements
This brief contains forward-looking information regarding clinical development, regulatory designations, and market opportunities. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive developments, and market conditions.-Fineline Info & Tech